Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-Glycoprotein), and pravastatin (OATP1B1) as probe drugs

Journal of Clinical Pharmacology

Volumn 53, Issue 6, 2013, Pages 654-661

  Ieiri, Ichiro ^a   Tsunemitsu, Shyohei ^a   Maeda, Kazuya ^b   Ando, Yukie ^a   Izumi, Noritomo ^c   Kimura, Miyuki ^c   Yamane, Naoe ^d   Okuzono, Tsuyoshi ^e   Morishita, Mariko ^f   Kotani, Naoki ^b   Kanda, Eri ^c   Deguchi, Mariko ^c   Matsuguma, Kyoko ^c   Matsuki, Shunji ^c   Hirota, Takeshi ^a   Irie, Shin ^c   Kusuhara, Hiroyuki ^b   Sugiyama, Yuichi ^g  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

^d Nishiwaki Laboratory   (Japan)

^e SEKISUI CHEMICAL CO LTD   (Japan)

^f HOSHI UNIVERSITY   (Japan)

^g RIKEN   (Japan)

Author keywords

Boosting; Fexofenadine; Midazolam; Ritonavir; Saquinavir

Indexed keywords

ANION TRANSPORT PROTEIN; CYTOCHROME P450 3A4; FEXOFENADINE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTING POLYPEPTIDE B1; PRAVASTATIN; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; LIVER; MALE; MIDAZOLAM; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PRAVASTATIN; RITONAVIR; SAQUINAVIR; TANDEM MASS SPECTROMETRY; TERFENADINE; YOUNG ADULT;

EID: 84880271700     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.62     Document Type: Article

References (39)

1. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44(2):190-194.
2. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450 mediated metabolism of the HIV 1 protease inhibitor ritonavir (ABT 538) in human liver microsomes. J Pharmacol Exp Ther. 1996;277(1):423-431.
3. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P4503A4: potential contribution to high first pass metabolism. Drug Metab Dispos. 1997;25(2):256-266.
4. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther. 1998;63(4):453- 464.
5. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once daily regimens of soft gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus negative adults. Antimicrob Agents Chemother. 2000;44(10):2672-2678.
6. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73-84.
7. Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X. Drug-drug interaction study of ketoconazole and ritonavir boosted saquinavir. Antimicrob Agents Chemother. 2009;53(2):609-614.
8. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Effect of saquinavir/ritonavir on P glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther. 2010;48(3): 192-199.
9. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009;85(1):64-70.
10. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr. 2008;49(4):358-368.
11. Profit L, Eagling VA, Back DJ. Modulation of P glycoprotein function in human lymphocytes and Caco 2 cell monolayers by HIV 1 protease inhibitors. AIDS. 1999;13(13):1623-1627.
12. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco 2 cell monolayers. Pharm Res. 1998;15(3):423-428.
13. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004;26(3):322-330.
14. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW. Time dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol. 2006; 46(7):758-767.
15. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and Pglycoprotein activities. Clin Pharmacol Ther. 2008;84(4):506-512.
16. Su Y, Zhang X, Sinko PJ. Human organic anion transporting polypeptide OATP A (SLC21A3) acts in concert with P glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004;12(1):49-56.
17. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of druginduced hyperbilirubinemia. Chem Biol Interact. 2004;150(2):179- 187.
18. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40(3):163-176.
19. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20(2):112-120.
20. Yoshida K, Maeda K, Sugiyama Y. Transporter mediated drug-drug interactions involving OATP substrates: Predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 2012;91(6):1053- 1064.
21. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non radiolabeled compounds. Adv Drug Deliv Rev. 2011;63(7):532- 538.
22. Sugiyama Y, Yamashita S. Impact of microdosing clinical study - why necessary and how useful? Adv Drug Deliv Rev. 2011;63(7): 494-502.
23. Diczfalusy U, Nylén H, Elander P, Bertilsson L. 4b Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol. 2011;71(2):183-189.
24. Ueno K, Sato H. Sex related differences in pharmacokinetics and pharmacodynamics of anti hypertensive drugs. Hypertens Res. 2012;35(3):245-250.
25. Paine MF, Shen DD, Kunze KL, et al. First pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996; 60(1):14-24.
26. Thummel KE, O'Shea D, Paine MF, et al. Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3Amediated metabolism. Clin Pharmacol Ther. 1996;59(5):491-502.
27. Croft M, Keely B, Morris I, Tann L, Lappin G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012;51(4):237-246.
28. Kim KA, Park JY. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol. 2010;66(7):721-725.
29. Lappin G, Shishikura Y, Jochemsen R, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40(2): 125-131.
30. Usansky HH, Hu P, Sinko PJ. Differential roles of P glycoprotein, multidrug resistance associated protein 2, and CYP3A on saquinavir oral absorption in Sprague Dawley rats. Drug Metab Dispos. 2008;36(5):863-869.
31. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73(6): 554-565.
32. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006;79(5):427-439.
33. Tomaru A, Takeda Morishita M, Banba H, Takayama K. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. Drug Metab Pharmacokinet. 2012. Norvir™ (ritonavir) Tablet Oral Solution. Interview Form (ver.2) released from Abbott. Japan Co., Ltd., Tokyo, Japan.
34. Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood to plasma drug concentration ratio. Biopharm Drug Dispos. 2010;31(5-6):286-297.
35. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998;50(3):387-412.
36. Hsu A, Granneman GR, Marsh K, et al. Single dose pharmacokinetics of ritonavir, an HIV protease inhibitor (in press).
37. Hsu A, Granneman GR, Witt G, et al. Multiple dose pharmacokinetics of ritonavir in human immunodeficiency virusinfected subjects. Antimicrob Agents Chemother. 1997;41(5):898- 905.
38. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006;80(3):203-215.
39. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858(1-2):118-128.